03 September 2010
Keywords: Nycomed, Instanyl, Scotland, NHS, Cancer pain
Article | 10 November 2009
Switzerland-headquartered Nycomed says it welcomes the decision by the Scottish Medicines Consortium (SMC) on Instanyl, (intranasal fentanyl), the only fast-acting intranasal treatment licensed for breakthrough cancer pain. The SMC decision means that cancer patients in Scotland will now have another option for the treatment of breakthrough cancer pain within the National Health Service in Scotland, the privately-owned drugmaker notes.
In its submission to the SMC, Nycomed estimated a net drug budget impact of £11,000 ($18,260) in year one, rising to £418,000 in year five. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.